Vaccines against biologic agents: Uses and developments

Respiratory Care Clinics of North America

Volumn 10, Issue 1, 2004, Pages 123-146

  Ales, Noel C ^a   Katial, Rohit K ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BOTULINUM ANTISERUM; BOTULINUM TOXIN A; PLAGUE VACCINE; POLYCLONAL ANTISERUM; SMALLPOX VACCINE; TULAREMIA VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

ABSCESS; ANAPHYLAXIS; ANTHRAX; BACTERIAL INFECTION; BIOLOGICAL WARFARE; BOTULISM; CHILL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECZEMA; EDEMA; ERYTHEMA; FATIGUE; FEVER; GUILLAIN BARRE SYNDROME; HANTAVIRUS; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INJECTION PAIN; KERATITIS; LASSA VIRUS; MALAISE; MARBURG VIRUS; MOUSE; MULTIPLE SCLEROSIS; MYALGIA; MYOCARDITIS; NAUSEA; NONHUMAN; PLAGUE; POSTVACCINAL ENCEPHALITIS; REVIEW; SEPSIS; SKIN INDURATION; SKIN MANIFESTATION; SMALLPOX; TULAREMIA; VACCINIA; VIRUS ENCEPHALITIS; VIRUS HEMORRHAGIC FEVER; YERSINIA PESTIS;

ANTHRAX VACCINES; ARENAVIRUSES, NEW WORLD; BACTERIAL VACCINES; BIOTERRORISM; CLOSTRIDIUM BOTULINUM; DISASTER PLANNING; FRANCISELLA TULARENSIS; HUMANS; RESPIRATORY TRACT INFECTIONS; SMALLPOX VACCINE; UNITED STATES; VACCINES; VIRAL VACCINES; YERSINIA PESTIS;

EID: 1342283211     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(03)00053-4     Document Type: Review

References (70)

1. Noah D.L. Huebner K.D. Darling R.G. et al. The history and threat of biological warfare and terrorism Emerg Med Clin North Am 20 2 2002 255-271
2. Dixon T.C. Meselson M. Guillemin A. et al. Anthrax N Engl J Med 341 1999 815-826
3. Meselson M. Guillemin J. Hugh-Jones M. et al. The Sverdlovsk anthrax outbreak of 1979 Science 266 5188 1994 1202-1207
4. Ingelesby T.V. O'Toole T. Henderson D.A. et al. Anthrax as a biological weapon 2002. Updated recommendations for management JAMA 288 17 2002 2236-2253
5. Nass M. Anthrax vaccine. Model of a response to the biological warfare threat Infect Dis Clin N Am 13 1 1999 187-210
6. Pittman R.P. Aluminum-containing vaccine associated adverse events: role of route of administration and gender Vaccine 20 2002 S48-S50
7. Ivins B.E. Fellows P.F. Nelson G.O. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea pigs Vaccine 12 10 1994 872-882
8. Ivins B.E. Fellows P.F. Pitt M.L.M. et al. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys Salisbury Med Bull 87 Suppl 1995 125-126
9. Brachman P.S. Gold S.A. Plotkin R. et al. Field evaluation a human anthrax vaccine Am J Public Health 52 1962 356-363
10. Freidlander A.M. Welkos S.L. Pitt M.L.M. et al. Postexposure prophylaxis against experimental inhalation anthrax J Infect Dis 167 1993 1239-1242
11. Centers for Disease Control and Prevention Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 49 RR-15 2000 1-20
12. Surveillance for adverse events associated with anthrax vaccination: US Department of Defense 1998-2000 MMWR 49 16 2000 341-345
13. Pittman P.R. Gibbs P.H. Cannon T.L. et al. Anthrax vaccine: short-term safety experience in humans Vaccine 20 2001 972-978
14. Committee on Health Effects Associated with Exposure During the Gulf War. Institute of Medicine. Available at: http://www.nap.edu/ Accessed October 23, 2000.
15. Joellenbeck LM, Zwanziger L, Durch JS, et al. The anthrax vaccine: is it safe? Does it work? Washington DC: National Academy Press. Available at: http://www.nap.edu/catalog/10310.html. Accessed March 3, 2002
16. Ivins B.E. Welkos S.L. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis Infect Immun 54 1986 537-542
17. Ivins B.E. Welkos S.L. Knudson G.B. et al. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen Infect Immun 58 1990 303-308
18. Ivins B.E. Fellows P. Pitt L. et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs Vaccine 13 1995 1779-1784
19. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 50 RR-10 2001 1
20. Fauci A.S. NIAID biodefense research agenda for CDC category A agents. Available at: http://www.niaid.nih.gov/biodefense/research/bioresearchagenda.pdf. Accessed February 27, 2002.
21. Breman J.G. Henderson D.A. Diagnosis and management of smallpox N Engl J Med 346 17 2002 1300-1308
22. Cherry J.D. McIntosh K. Connor J.D. et al. Clinical and serologic study of four smallpox vaccines comparing variations in dose and route of administration; primary percutaneous vaccines J Infect Dis 135 1977 145-154
23. Polak M.F. Beunders B.J.W. Van Derlverff A.R. et al. A comparative study of clinical reactions observed after application of several smallpox vaccines in primary vaccination of young adults Bull World Health Organ 29 1963 311-322
24. Cono J. Casey C.G. Bell D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians MMWR 52 2003 1-29
25. Public health emergency preparedness and response. Available at: http://www.bt.cdc.gov/agent/smallpox/vaccination/takes-nontakes-.asp. Accessed February 27, 2003.
26. Henderson D.A. Inglesby T.V. Bartlett J.G. et al. Smallpox as a biological weapon: medical and public health management JAMA 281 22 1999 2127-2137
27. el-Ad B. Roth Y. Winder A. et al. The persistence of neutralizing antibodies after revaccination against smallpox J Infect Dis 161 3 1990 446-448
28. Centers for Disease Control, and Prevention. Smallpox vaccination adverse events training module. CDC Available at: http://www.bt.cdc.gov/training/smallpoxvaccine/reactions/about_vac_html. Accessed February 27, 2003.
29. Lane J.M. Ruben F.L. Neff J.M. et al. Complications of smallpox vaccination, 1968 N Engl J Med 281 22 1969 1201-1208
30. Engler J.M. Kenner J. Donald Y.M. Smallpox vaccination: risk considerations for patients with atopic dermatitis J Allergy Clin Immunol 110 3 2002 357-365
31. Lane J.M. Ruben F.L. Neff J.M. et al. Complications of smallpox vaccination, 1968: results of ten state wide surveys N Engl J Med 122 4 1970 303-309
32. Frey S.E. Couch R.B. Tacket C.O. et al. Clinical responses to undiluted and diluted smallpox vaccine N Engl J Med 346 17 2002 1265-1274
33. Smallpox safety summary. DOD Smallpox Vaccination Program. Available at: http://www.smallpox.army.mil/media/pages/SPSafetySum.asp . Accessed Feb 12, 2003.
34. Nannig W. Prophylactic effect of antivaccinia gammaglobulin against post-vaccine encephalitis Bull World Health Organ 27 1962 317-324
35. Rosenthal S.R. Merchlinsky M. Kleppinger C. et al. Developing new smallpox vaccines Emerg Infect Dis 7 6 2001 920-926
36. Hirayama M. Smallpox vaccinations in Japan. In: The vaccination: theory and practice 1975 113-124 International Medical Foundation of Japan Tokyo
37. Sutter G. Moos B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus Dev Biol Stand 884 1995 195-200
38. Bozeman W.P. Dilbero D. Schauben J.L. Biological and chemical weapons of mass destruction Emerg Med Clin N Am 10 4 2002 975-993
39. Franz D.R. Jahrling P.B. Friedlander A.M. et al. Clinical recognition and management of patients exposed to biological warfare agents JAMA 278 5 1997 399-411
40. Gradon J.D. Plague pneumonia Curr Infect Dis Rep 4 2002 244-248
41. Inglesby T.V. Dennis D.T. Henderson D.A. et al. Plague as a biological weapon: medical and public health management JAMA 283 17 2000 2281-2290
42. Plague vaccine. In: Mosby's Drug Consult, 12th edition. 2002. Available at: http://home.mdconsult.com/das/drug/view/26701366/1/2050/top?sid=165273780. Accessed February 27, 2003.
43. McGovern T.W. Friedlander A.M. Plague. In: Zajtchuk R. Bellamy R.F. (Eds.), Textbook of military medicine. Medical aspects of chemical and biological warfare 1997 483-503 Office of the Surgeon General: Department of the Army Washington (DC)
44. Plague in Vietnam Lancet 7546 1968 799-800
45. Evans M.E. Friedlander A.M. Tularemia. In: Zajtchuk R. Bellamy R.F. (Eds.), Textbook of military medicine. Medical aspects of chemical and biological warfare 1997 503-508 Office of the Surgeon General: Department of the Army Washington (DC)
46. Levy P.D. Chiang W.K. Update on emerging infections: news from the Centers for Disease Control and Prevention Ann Emerg Med 40 3 2002 357-360
47. Dennis D.T. Inglesby T.V. Henderson D.A. et al. Tularemia as a biological weapon: medical and public health management JAMA 285 21 2002 2763-2773
48. Tärnvik A. Nature of protective immunity to Francisella tularensis Rev Infect Dis 11 1989 440-451
49. Fortier A.H. Polsinelli T. Green S.J. et al. Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules Infect Immun 60 1992 817-825
50. Anthony L.S.D. Ghadirian E. Nestel F.P. et al. The requirement for gamma interferon in resistance of mice to experimental tularemia Microb Pathog 7 1989 421-428
51. Foshay L. Hesselbrock W.H. Wittenberg M.J. et al. Vaccine prophylaxis against tularemia in man Am J Public Health 32 1942 1131-1145
52. Burke D.S. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis J Infect Dis 135 1 1977 55-60
53. Choi E. Tick-borne diseases. Tularemia and Q fever Med Clin N Am 86 2002 393-416
54. Sjostedt A. Sandstrom G. Tarnvik A. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium Infect Immun 60 1992 2855-2862
55. Fulop M. Mastroeni P. Green M. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis Vaccine 19 31 2001 4465-4472
56. Khlebnikov V.S. Golovliov I.R. Kulevatsky D.P. et al. Outer membrane of a LPS-protein complex LPS-17 kDa protein as chemical tularemia vaccines FEMS Immunol Med Microbiol 13 3 1996 227-233
57. Aron S.S. Schechter R. Ingelsby T.V. et al. Botulinum toxin as a biological weapon: medical and public health management JAMA 285 8 2001 1059-1070
58. Middlebrooke J.L. Franz D.R. Botulinum toxins. In: Zajtchuk R. Bellamy R.F. (Eds.), Textbook of military medicine. Medical aspects of chemical and biological warfare 1997 643-647 Office of the Surgeon General: Department of the Army Washington (DC)
59. Bleck T.P. Clostridium botulinum (botulism). In: Mandell G.L. (Ed.), Priniciples and practices of infectious diseases 5th edition 2000 2543-2547 Churchill Livingstone Orlando, FL
60. Tacket C.O. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism Am J Med 76 5 1984 794-798
61. Clayton M.A. Clayton J.M. Brown D.R. et al. Protective vaccination with recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli Infect Immun 63 7 1995 2738-2742
62. Borio L. Inglesby T. Peters C.J. et al. Hemorrhagic fever viruses as biological weapons. Medical and public health management JAMA 287 18 2002 2391-2405
63. Thompson M.J. Immunizations for international travel Prim Care 29 4 2002 787-796
64. Pittman P.R. Liu C.T. Cannon T.L. et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience Vaccine 18 2000 181-189
65. Fisher-Hoch S.P. Hutwagner L. Brown B. et al. Effective vaccine for Lassa fever J Virol 74 15 2000 6777-6783
66. Hevey M. Negley D. Pushko P. et al. Marburg virus vaccines based on alphavirus replicons protect guinea pigs and nonhuman primates Virology 251 1998 28-37
67. Sullivan N.J. Sanchez A. Rollin P.E. et al. Development of a preventive vaccine for Ebola virus infection in primates Nature 408 2000 605-609
68. Geisbert T.W. Pushko P. Anderson K. et al. Evaluation in nonhuman primates of vaccines against Ebola virus Emerg Infect Dis 8 5 2002 503-507
69. Christopher G.W. Cieslak T.J. Pavlin J.A. Biological warfare. A historical perspective JAMA 278 1997 412-417
70. Jones J. Terndrup T.E. Franz D.R. et al. Future challenges in preparing for and responding to bioterrorism events Emerg Med Clin N Am 20 2 2002 501-524